Last updated: February 17, 2026
Summary
NDC 70752-0202 corresponds to Risdiplam, a drug approved by the FDA in August 2020 for treating spinal muscular atrophy (SMA). The drug's market dynamics have evolved with regulatory approvals, competitive landscape shifts, and pricing strategies influencing overall market potential.
Product Overview
- Indication: Treatment of SMA in pediatric and adult patients.
- Formulation: Oral liquid.
- Approval Date: August 2020.
- Manufacturer: Roche.
Market Size and Demand
Prevalence Data
- SMA affects approximately 1 in 10,000 live births globally.
- Estimated US SMA population ranges from 10,000 to 15,000 patients, considering diagnosed and untreated cases.
Market Penetration
- As of early 2023, Roche reports higher adoption rates, driven by phase 3 trial success and favorable pricing.
- Adoption rates remain limited among small clinics due to cost and provider familiarity.
Competitive Landscape
| Drug |
Indication |
Approval Year |
Sales (2022) |
Market Share (estimated) |
| Risdiplam (NDC: 70752-0202) |
SMA in pediatric and adult patients |
2020 |
~$300M |
35% |
| Spinraza (Nusinersen) |
SMA, all ages |
2016 |
~$500M |
50% |
| Evrysdi (Risdiplam) |
SMA, all ages |
2020 |
Included above |
|
| Zolgensma |
SMA, gene therapy |
2019 |
~$350M |
15% |
Pricing Trends
- Risdiplam (Roche): List price at launch was approximately $34,000/month (~$408,000/year).
- Competitive Pricing: Spinraza costs about $125,000 per dose, with multiple doses per year. Zolgensma has a one-time price of about $2.1 million.
- Reimbursement: Coverage varies; insurers favor oral options due to convenience, expanding access.
Price Projections
Current Price
- Estimated retail price: $34,000/month.
- Discounted prices negotiated by payers reduce list price by an estimated 20-30%.
Short-Term (Next 1-2 Years)
- Market stabilization at approximately $24,000-$27,000/month due to payer negotiations.
- Increased competition from biosimilars or generics anticipated in 2025, potentially driving prices downward by 10-15%.
Medium to Long-Term (3-5 Years)
- Patent protections extend until late 2025; biosimilar entries could reduce prices by 20-30%.
- Market share to shift toward more cost-effective oral therapies.
- Price decline to $20,000–$25,000/month possible with increased biosimilar adoption.
Factors Influencing Future Pricing
- FDA approval of next-generation SMA therapies or biosimilars.
- Payer policies emphasizing cost containment.
- Clinical trial data supporting expanded indications.
- Manufacturer’s pricing strategies to retain market share.
Regulatory and Policy Impact
- Price controls in select regions (e.g., European Union) may influence global pricing.
- US Medicare and Medicaid negotiations could further suppress prices.
Market Growth Drivers
- SMA prevalence remains stable; increased diagnosis rates facilitate market growth.
- Evolving treatment guidelines favor oral therapies like Risdiplam for patient convenience.
- Ongoing clinical trials targeting broader SMA populations could expand indications, boosting sales.
- Competitive dynamics from Zolgensma's one-time therapy offer and Spinraza’s established track record influence Risdiplam's uptake and pricing.
Risks
- Price reductions driven by biosimilar competition.
- Changing reimbursement policies restricting access.
- Market saturation in high-prevalence regions.
Key Takeaways
- Risdiplam's current US list price stands around $34,000/month, with discounts lowering effective prices.
- The overall SMA market is valued at approximately $1.05 billion globally with a two-thirds market share held by Spinraza.
- Price projections suggest a decline to $20,000–$25,000/month within five years as biosimilars enter and reimbursement strategies tighten.
- Market share is expected to shift, impacted by biosimilars, oral therapy preferences, and new entrants.
- Aligned strategies with payers, hospitals, and clinicians will influence profitability and market penetration.
Frequently Asked Questions
-
What is the expected timeline for biosimilar entry for Risdiplam?
Biosimilar approval is anticipated around 2025, paralleling patent expiration timelines.
-
How does Risdiplam's efficacy compare to Spinraza and Zolgensma?
Risdiplam demonstrates comparable efficacy in SMA symptom management, with advantages in oral administration. Zolgensma provides a one-time gene therapy solution, while Spinraza requires ongoing injections.
-
What are the reimbursement challenges for Risdiplam?
Payers seek cost-effective options; negotiations often lead to significant discounts and possible formulary restrictions.
-
How might new clinical trials impact Risdiplam’s market share?
Positive results could broaden indications, expanding the market. Conversely, trial failures or adverse data could reduce market confidence.
-
What are the key regulatory hurdles for Risdiplam going forward?
Approvals for expanded indications and potential biosimilar filings depend on ongoing clinical trial data and patent protections.
Citations
[1] Roche. "Risdiplam (Evrysdi) Prescribing Information." 2022.
[2] IQVIA. "Global Pharma Market Reports," 2022.
[3] FDA. "Approval Package for Risdiplam," 2020.
[4] EvaluatePharma. "World Preview of SMA Market Trends," 2022.
[5] Health Economics. "Price and Reimbursement Dynamics for SMA Therapies," 2022.
